Literature DB >> 11435577

Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

H Nakai1, S R Yant, T A Storm, S Fuess, L Meuse, M A Kay.   

Abstract

Recombinant adeno-associated virus (rAAV) vectors stably transduce hepatocytes in experimental animals. Although the vector genomes are found both as extrachromosomes and as chromosomally integrated forms in hepatocytes, the relative proportion of each has not yet been clearly established. Using an in vivo assay based on the induction of hepatocellular regeneration via a surgical two-thirds partial hepatectomy, we have determined the proportion of integrated and extrachromosomal rAAV genomes in mouse livers and their relative contribution to stable gene expression in vivo. Plasma human coagulation factor IX (hF.IX) levels in mice originating from a chromosomally integrated hF.IX-expressing transposon vector remained unchanged with hepatectomy. This was in sharp contrast to what was observed when a surgical partial hepatectomy was performed in mice 6 weeks to 12 months after portal vein injection of a series of hF.IX-expressing rAAV vectors. At doses of 2.4 x 10(11) to 3.0 x 10(11) vector genomes per mouse (n = 12), hF.IX levels and the average number of stably transduced vector genomes per cell decreased by 92 and 86%, respectively, after hepatectomy. In a separate study, one of three mice injected with a higher dose of rAAV had a higher proportion (67%) of integrated genomes, the significance of which is not known. Nevertheless, in general, these results indicate that, in most cases, no more than approximately 10% of stably transduced genomes integrated into host chromosomes in vivo. Additionally, the results demonstrate that extrachromosomal, not integrated, genomes are the major form of rAAV in the liver and are the primary source of rAAV-mediated gene expression. This small fraction of integrated genomes greatly decreases the potential risk of vector-related insertional mutagenesis associated with all integrating vectors but also raises uncertainties as to whether rAAV-mediated hepatic gene expression can persist lifelong after a single vector administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435577      PMCID: PMC114425          DOI: 10.1128/JVI.75.15.6969-6976.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Mitotic stability of an episomal vector containing a human scaffold/matrix-attached region is provided by association with nuclear matrix.

Authors:  A Baiker; C Maercker; C Piechaczek; S B Schmidt; J Bode; C Benham; H J Lipps
Journal:  Nat Cell Biol       Date:  2000-03       Impact factor: 28.824

2.  Kinetics of recombinant adeno-associated virus-mediated gene transfer.

Authors:  A K Malik; P E Monahan; D L Allen; B G Chen; R J Samulski; K Kurachi
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro.

Authors:  C H Miao; K Ohashi; G A Patijn; L Meuse; X Ye; A R Thompson; M A Kay
Journal:  Mol Ther       Date:  2000-06       Impact factor: 11.454

4.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.

Authors:  M A Kay; C S Manno; M V Ragni; P J Larson; L B Couto; A McClelland; B Glader; A J Chew; S J Tai; R W Herzog; V Arruda; F Johnson; C Scallan; E Skarsgard; A W Flake; K A High
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

5.  Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells.

Authors:  S Ponnazhagan; D Erikson; W G Kearns; S Z Zhou; P Nahreini; X S Wang; A Srivastava
Journal:  Hum Gene Ther       Date:  1997-02-10       Impact factor: 5.695

6.  Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system.

Authors:  S R Yant; L Meuse; W Chiu; Z Ivics; Z Izsvak; M A Kay
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

7.  Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein.

Authors:  M Burton; H Nakai; P Colosi; J Cunningham; R Mitchell; L Couto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

8.  Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

Authors:  J A Wagner; A H Messner; M L Moran; R Daifuku; K Kouyama; J K Desch; S Manley; A M Norbash; C K Conrad; S Friborg; T Reynolds; W B Guggino; R B Moss; B J Carter; J J Wine; T R Flotte; P Gardner
Journal:  Laryngoscope       Date:  1999-02       Impact factor: 3.325

9.  Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction.

Authors:  C H Miao; H Nakai; A R Thompson; T A Storm; W Chiu; R O Snyder; M A Kay
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

10.  Persistent expression of canine factor IX in hemophilia B canines.

Authors:  H Chao; R Samulski; D Bellinger; P Monahan; T Nichols; C Walsh
Journal:  Gene Ther       Date:  1999-10       Impact factor: 5.250

View more
  162 in total

1.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Adeno-associated viruses undergo substantial evolution in primates during natural infections.

Authors:  Guangping Gao; Mauricio R Alvira; Suryanarayan Somanathan; You Lu; Luk H Vandenberghe; John J Rux; Roberto Calcedo; Julio Sanmiguel; Zahra Abbas; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

Review 3.  Self-complementary adeno-associated viral vectors for gene therapy of hemophilia B: progress and challenges.

Authors:  Deepak Raj; Andrew M Davidoff; Amit C Nathwani
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

4.  Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.

Authors:  Clare E Thomas; Theresa A Storm; Zan Huang; Mark A Kay
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Adeno-Associated Virus-Based Gene Therapy for Lifelong Correction of Genetic Disease.

Authors:  Christian M Brommel; Ashley L Cooney; Patrick L Sinn
Journal:  Hum Gene Ther       Date:  2020-08-21       Impact factor: 5.695

6.  High-resolution genome-wide mapping of transposon integration in mammals.

Authors:  Stephen R Yant; Xiaolin Wu; Yong Huang; Brian Garrison; Shawn M Burgess; Mark A Kay
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

7.  Large-scale analysis of adeno-associated virus vector integration sites in normal human cells.

Authors:  Daniel G Miller; Grant D Trobridge; Lisa M Petek; Michael A Jacobs; Rajinder Kaul; David W Russell
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 8.  Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency.

Authors:  Timothy C Nichols; Aaron M Dillow; Helen W G Franck; Elizabeth P Merricks; Robin A Raymer; Dwight A Bellinger; Valder R Arruda; Katherine A High
Journal:  ILAR J       Date:  2009

9.  Characterization of genome integrity for oversized recombinant AAV vector.

Authors:  Biao Dong; Hiroyuki Nakai; Weidong Xiao
Journal:  Mol Ther       Date:  2009-11-10       Impact factor: 11.454

10.  Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-09-09       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.